Eikon Therapeutics EIKN
Eikon Therapeutics Q1 FY26: net loss $83.0M; diluted EPS −$2.46
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001193125-26-216791
Key figures from this report
These are the numbers Eikon Therapeutics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$83.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$2.46No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$161.2MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$89.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
- Alpha Cognition ACOG public float $149M, Jun 30, 2025
- Adaptimmune Therapeutics ADAP
- Adma Biologics ADMA public float $4.2B, Jun 30, 2025
- Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025